UroGen Pharma Reports Strong Revenue Growth Driven by Zosturi Sales
UroGen Pharma (NASDAQ: URGN) has demonstrated significant commercial momentum following the FDA approval of its bladder cancer treatment, Zosturi. The company reported quarterly total revenue of $89.0 million, a substantial increase from $27.5 million in the previous year. This growth was primarily driven by Zosturi, which generated $68.0 million in quarterly net product revenue, up 35% from the prior quarter. The company's financial health is improving as its net loss shrank to $1.5 million, down from $33.3 million a year ago, with management projecting profitability in the fourth quarter. Market adoption appears robust; unique prescribers increased to 662, and repeat prescribers now account for approximately 50% of total writers. This indicates that physicians are integrating the gel-based mitomycin delivery system into their standard practice.
Coverage
- UroGen Pharma Reports Strong Revenue Growth Driven by Zosturi Sales
- UroGen Pharma Reports 35% Sequential Revenue Growth for ZUSDURI in Q3 2026
- Axsome Therapeutics Reports 52% Revenue Growth Driven by Auvelity Sales
- AMD Non-GAAP EPS of $2.09 beats by $0.15, revenue of $13.38B beats by $290M
- Crexendo Non-GAAP EPS of $0.12 beats by $0.03, revenue of $25.2M beats by $0.06M
- Pfizer Reports Strong Revenue and EPS Beat Driven by Primary Care Growth
- LENZ Therapeutics Reports Q3 2026 Revenue Growth Driven by Telehealth and Advertising